Country Club Bank Sells 557 Shares of Stryker Co. (NYSE:SYK)

Country Club Bank lessened its position in Stryker Co. (NYSE:SYK) by 8.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,056 shares of the medical technology company’s stock after selling 557 shares during the quarter. Country Club Bank’s holdings in Stryker were worth $2,194,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Stryker by 37.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 41,366 shares of the medical technology company’s stock valued at $15,114,000 after purchasing an additional 11,247 shares during the period. Weaver Capital Management LLC lifted its stake in shares of Stryker by 4.6% in the 4th quarter. Weaver Capital Management LLC now owns 3,630 shares of the medical technology company’s stock valued at $1,307,000 after purchasing an additional 159 shares during the period. Hager Investment Management Services LLC purchased a new position in shares of Stryker in the 4th quarter valued at approximately $3,800,000. Stratos Wealth Advisors LLC lifted its stake in shares of Stryker by 5.6% in the 4th quarter. Stratos Wealth Advisors LLC now owns 4,409 shares of the medical technology company’s stock valued at $1,588,000 after purchasing an additional 232 shares during the period. Finally, Stratos Wealth Partners LTD. lifted its stake in shares of Stryker by 5.3% in the 4th quarter. Stratos Wealth Partners LTD. now owns 17,137 shares of the medical technology company’s stock valued at $6,170,000 after purchasing an additional 859 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research analyst reports. Citigroup raised their target price on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Barclays lifted their price objective on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Canaccord Genuity Group lifted their price objective on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Finally, BTIG Research lifted their price objective on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Stock Performance

Shares of SYK opened at $392.55 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The firm has a market capitalization of $149.65 billion, a P/E ratio of 50.59, a PEG ratio of 2.78 and a beta of 0.96. The business has a fifty day moving average of $376.81 and a 200 day moving average of $363.64.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company earned $3.46 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 13.5 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were issued a $0.84 dividend. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s payout ratio is presently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.